Treatment of hepatitis C (HCV) with direct-acting antiviral agents does not appear to increase the risk of hepatocellular carcinoma (HCC) in individuals with cirrhosis, researchers from France report.
Continue reading: https://www.managedhealthcareconnect.com/content/direct-antiviral-therapy-hep-c-may-not-boost-hepatocellular-carcinoma-risk
Study: Gastroenterology 2018
On This Blog
HCC during and after direct-acting antiviral therapy in patients with hepatitis C
Index of research articles investigating the possible risk of developing liver cancer (hepatocellular carcinoma, or HCC) during and after direct-acting antiviral therapy in patients with hepatitis C.
No comments:
Post a Comment